Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

AstraZeneca: Clinical Trials & FDA Approval Profile

AstraZeneca (Cambridge, UK / Wilmington, DE) sponsors 534 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 300 active protocols (134 recruiting now), 175 completed protocols, and 81 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)11.1%
Median Closed Enrollment vs National (145 pts)181 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for AstraZeneca
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)534
Active Pipeline (Recruiting Now)300 (134)
Completed vs Stopped Early175 / 59 (11.1%)
Median Closed Actual Enrollment181 participants
Physical Hospital Site Disclosure0.9% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals81 (21 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With AstraZeneca
Hospital Research SiteLocationShared Protocols
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CA3
Massachusetts General HospitalBoston, MA3
Hospital Universitari Vall d'HebronBarcelona3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by AstraZeneca
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04248465An Efficacy and Safety Study of Ravulizumab in ALS ParticipantsPhase IIITERMINATED
NCT04369469Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe PneumoniaPhase IIITERMINATED

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the AstraZeneca Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI